Nxera Pharma Co., Ltd.
4565.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | ¥7 | ¥8 | ¥7 | ¥7 |
| % Growth | -20.1% | 27.2% | -3% | – |
| Cost of Goods Sold | ¥3 | ¥2 | ¥2 | ¥2 |
| Gross Profit | ¥4 | ¥7 | ¥5 | ¥5 |
| % Margin | 60.4% | 78% | 75.7% | 69% |
| R&D Expenses | ¥4 | ¥4 | ¥4 | ¥3 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥4 | ¥4 | ¥4 | ¥4 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥2 |
| Other Operating Expenses | ¥0 | ¥0 | ¥0 | -¥0 |
| Operating Expenses | ¥8 | ¥8 | ¥8 | ¥7 |
| Operating Income | -¥3 | -¥1 | -¥2 | -¥2 |
| % Margin | -51.7% | -11.1% | -37.3% | -24.6% |
| Other Income/Exp. Net | ¥0 | -¥1 | ¥0 | -¥1 |
| Pre-Tax Income | -¥3 | -¥2 | -¥2 | -¥2 |
| Tax Expense | -¥1 | ¥1 | -¥1 | -¥1 |
| Net Income | -¥2 | -¥2 | -¥1 | -¥1 |
| % Margin | -24.8% | -28.1% | -11.4% | -19.5% |
| EPS | -18.48 | -26.38 | -8.45 | -14.86 |
| % Growth | 29.9% | -212.2% | 43.1% | – |
| EPS Diluted | -18.48 | -26.38 | -8.45 | -14.85 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥0 | ¥0 | ¥0 | ¥0 |
| Interest Expense | ¥0 | ¥1 | ¥0 | ¥0 |
| Depreciation & Amortization | ¥1 | ¥1 | ¥1 | ¥1 |
| EBITDA | -¥2 | ¥1 | -¥1 | -¥2 |
| % Margin | -26.7% | 9.3% | -12.4% | -23% |